Amarin to eliminate 50% of staff following FDA Advisory Committee vote

Wednesday, October 23, 2013

Amarin, a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, plans to reduce operating expenses by eliminating approximately 50% of its staff worldwide, following the recent recommendation of the FDA Endocrinologic and Metabolic Drugs Advisory Committee against the potential Vascepa (icosapent ethyl) label expansion.

[Read More]

FDA approves Vascepa for severe hypertriglyceridemia

Friday, July 27, 2012

The FDA has approved Vascepa (icosapent ethyl) capsules as an adjunct to diet to reduce triglyceride (TG) levels in adult patients with severe hypertriglyceridemia (TG ≥ 500mg/dL), according to Amarin, a Bedminster, N.J.-based biopharmaceutical company focused on cardiovascular health.

[Read More]

Amarin reveals positive results from ANCHOR trial for AMR 101

Monday, April 18, 2011

Amarin, a clinical-stage biopharmaceutical company focusing on cardiovascular disease, reported positive, statistically significant results from its ANCHOR trial for the company’s lead product candidate, AMR101.,  The trial was a multi-center, placebo-controlled, randomized, double-blind, 12-week pivotal study, that enrolled 702 patients.  The phase III trial met its primary and secondary efficacy endpoints for both the 4 gram and 2 gram daily doses.

[Read More]